Progressive multifocal leukoencephalopathy (PML) is caused by the human polyomavirus JC (JCV), and there are at least 4 different genotypes of JCV in the United States. Type 1 strains are of European origin, whereas type 2 and 3 strains are of Asian and African origin, respectively. JCV type 4 strains are derived from a type 1/3 recombinant. In this study, the genotype distribution of JCV strains found in brain tissue or cerebrospinal fluid of 50 PML patients was compared with JCV genotypes excreted in the urine of 103 control subjects. Type determination was based on the polymerase chain reaction -amplified partial sequence of the VP1 coding gene and the noncoding region left of ori. Brain tissues from patients with PML were infected with a significantly higher proportion of JCV type 2 strains than were urine samples from the control group (P Å .004). This evidence indicates a biologic difference between JCV genotypes and suggests a difference in their potential to cause PML.
JC virus (JCV) infects 70% -90% of the adult population individuals [8, 9] . The most common initial symptoms of PML include motor weakness, ataxia, visual defects, and cognitive [1] . The virus regularly persists in the kidneys [2] , and by use of polymerase chain reaction (PCR), viral DNA can be detected and speech deficits [7, 8, 10 ]. The outcome is usually fatal within 3 months to 1 year after onset [8] . Survival beyond 1 in the urine of 30% -40% of healthy adults at any given time [3] . Peripheral blood lymphocytes also harbor the virus [4, 5] .
year is associated with manifestation of PML early in the course of AIDS, a higher CD4 / lymphocyte count, a prominent inIn association with immunodeficiency, JCV establishes a lytic infection of oligodendrocytes and an abortive infection of astroflammatory response in biopsied lesions, and contrast enhancement on magnetic resonance imaging [11] . Lesions are most cytes [6] and causes the central demyelinating disease progressive multifocal leukoencephalopathy (PML). For 25 years, only commonly found in white matter and can be present in any part of the central nervous system. The diagnosis of PML Ç200 cases of PML were reported worldwide [7] ; however, that number has increased rapidly with the spread of human includes the detection of demyelinating lesions by magnetic resonance imaging [8] and the demonstration of the characterisimmunodeficiency virus type 1 (HIV-1) infection [8] . PML is found in Ç5% of autopsied AIDS patients [9] . tic pathology or the presence of the virus in a brain biopsy [12] . PCR detection of JCV DNA in cerebrospinal fluid (CSF) The course and pathology of PML in persons with AIDS are similar to those as originally described in HIV-negative is indicative of the presence of PML lesions [13, 14] and provides an additional approach to diagnosis. The 5.1-kb super-coiled circular DNA of JCV encodes six Received 9 August 1996; revised 5 February 1997. or more proteins [15] . Viral genes are transcribed bidirection- previously [24] . amplified by primers JRR-25 and -28 from brain tissue and CSF before PCR. Viral DNA was amplified using primers BAM-1 and BAM-2 with a 5 overlap at the restriction enzyme site (GGATCC; from PML patients. Amplification of the regulatory region right of ori with primers JRR-1 and -8 yields a fragment that lacks the table 2). The combination of thermostable DNA polymerases with and without 3-5 exonuclease activity facilitates long-range PCR, three typing sites left of ori but permits characterization of regulatory region rearrangements. All short-range PCRs were performed and buffer additives enhance strand separation (GeneAmp XL PCR; Perkin-Elmer Cetus). The reaction was run for 39 cycles using UlTma DNA polymerase with 3-5 proofreading activity (Perkin-Elmer Cetus, Norwalk, CT) in a standard PCR buffer conwith increasing annealing and extension time (6-12 min) at 64ЊC and denaturation (30 s) at 94ЊC, followed by a final extension (10 taining 1.5 mM Mg 2/ . PCR amplification of the complete JCV genome. JCV-positive min) at 72ЊC. The reaction was stopped at 4ЊC. Direct cycle sequencing. After gel purification according to samples were further processed for complete PCR amplification of the 5.1-kb JCV genome as described previously [30] . In brief, the Qiagen procedure (Qiagen, Chatsworth, CA), both short-and long-range PCR products were used as templates for direct cycle the lysed sample was digested with the restriction enzyme BamHI sequencing as described previously [26] . In brief, primers JLP-1 figure 3. JCV DNA was amplified by PCR with primers JLP- deoxyguanosine at typing site 5039 in type 2 was replaced by deoxyadenosine. Since deoxyadenosine at this site is unique and the partial VP1 sequence was unambiguous, this strain was classified as type 2. Strain number 210 had a point mutation Results at position 5040, which is not a typing site (figure 2). years. The group included 72 females and 141 males, of which Age and JCV excretion. The frequency of JCV excretion with increasing age in HIV-positive patients did not differ a total of 91 (42.7%) tested positive for JCV excretion, as detected by PCR, in at least 1 urine sample. More than 1 urine significantly from that in HIV-negative individuals; however, the proportion of individuals excreting JCV generally increased sample was analyzed for 54 individuals. Excretion status was stable in 24 of the excreters and in 21 of the nonexcreters. For with age. In both groups, ú40% of persons ú30 years old tested positive for JCV DNA in a single urine sample. Infection 1 excreter over a 17-month period, 9 consecutive urine samples were analyzed for JCV genotype, with identical results. One with HIV-1 did not increase the number of individuals excreting JCV. For patients from whom a second urine sample was nonexcreter was tested seven times and remained negative. In 9 persons, the excretion status changed without a change in obtained, only results for the first samples were included in this age analysis. the JCV genotype excreted: 4 changed from JCV-positive to JCV-negative, 2 from negative to positive, 1 from negative to JCV genotypes. On the basis of the sequence of the JLP-1 -and -4 -amplified fragment within the VP1 gene ( figure 3 ), positive to negative, and 2 from positive to negative to positive to negative. all 4 major JCV genotypes could be found in urine samples from persons without PML (table 3) . Four males showed signs Controls with HIV-1 infection. Urine samples from 32 HIV-positive persons without PML (31 men, 1 woman; age of coinfection with 2 different JCV genotypes: types 1 and 2 strains in 2 persons, types 2 and 3 in another, and 2 distinguishrange, 31 -68 years) were tested by PCR for JCV DNA excretion: Samples tested with primers JLP-1 and -4 were positive able subtypes of JCV type 1 in a 38-year-old man from Pennsylvania. Among a total of 107 detected strains, JCV type 1 was in at least 1 sample in 12 male donors (38%). A second sample taken 1 -6 months later was available from 13 patients: excrethe most prevalent, accounting for 55 (58%) of 95 strains in HIV-negative persons and 8 (67%) of 12 strains in HIV-position of a specific genotype was confirmed in 3, excretion of JCV was transient in 3, and 7 initial nonexcreters remained tive persons (total: 63/107 [59%]). JCV type 2 strains accounted for 22 (23%) of 95 strains in HIV-negative persons and 3 (25%) negative for JCV in the urine. distributions. When results for HIV-positive controls from Los Angeles were compared with results for HIV-negative controls also from Los Angeles, the excretion of JCV type 2 was marginally increased, and the frequency of type 4 was decreased type 2 and non -type 2 strains differed significantly in brain in the HIV-positive cohort, but the genotype distribution of tissue from PML patients and urine samples from controls, the type 2 and non -type 2 strains was not significantly different numbers of JCV strains were analyzed in a 2 1 2 contingency (P Å 1.0). table, using the x 2 statistic. The type 2 proportion was signifi-A comparison of the 107 JCV strains from the East (Pennsylcantly higher (P Å .004) in strains from all PML tissues (AIDS vania and Maryland; total, 45 strains) and the West (California;
PML and non-AIDS PML) than in strains from urine samples total, 62 strains, with 2 unclassified) showed that type 1 domiof all non-PML individuals (HIV-positive and HIV-negative) nates in both groups (64% in the East, 52% in the West), (table 4) . By use of a 2 1 4 contingency table for the x 2 followed by type 2 (18% in the East, 28% in the West). Type analysis of the distribution of JCV types 1 -4 in all strains 3 strains accounted for 2% (East) and 3% (West), and type 4 from PML and non-PML individuals, the significant difference strains were similarly represented with 16% (East) and 11% in genotype distribution was confirmed (P Å .011). To mini-(West). Therefore, the geographic origin of the urine samples mize the possible influence of geographic variation in the genofrom ethnically similar groups (table 1) did not significantly type distribution, the 27 JCV strains from PML patients living influence the JCV type distribution of type 2 and non -type 2 in the Los Angeles area (16 type 2, 11 non -type 2) were strains (P Å .35).
compared statistically with 60 urinary JCV strains (17 type 2, Genotype distribution can vary with different ethnic groups.
43 non -type 2) of individuals with comparable ethnicity from Of all classified JCV strains from both PML and control groups, the same geographic area. This comparison confirmed the sig-24 (17%) of the 144 isolates came from 9 Hispanic Americans nificantly increased frequency of type 2 strains in PML tissue and 15 African Americans. In the Hispanic-American group, (P Å .012). JCV type 2 was identified four times, type 1 three times, and
As mentioned above, 6 persons (2 with PML, 4 controls) type 4 once. A 55-year-old male excreted an unclassified JCV were infected with 2 distinguishable JCV strains. Repeating strain. Among the African Americans, JCV type 1 was found the above analysis in 2 1 2 contingency tables but excluding five times, JCV type 4 was found four times, and JCV types data from these doubly infected patients for all PML strains 2 and 3 were found three times each. Of note, all three examples and all controls (P Å .002) and the California cohorts (P Å of type 3 strains in this study were from African Americans.
.014) underlines the significantly increased frequency of type As mentioned above, the ethnicity of the probands in the PML 2 strains in PML patients. and control groups was comparable. The proportion of JCV-
The genotype distribution among 37 isolates from AIDS positive Americans of European, African, or Hispanic origins PML patients was 19 type 2 and 18 non -type 2 strains, comwas (in percents) 93:7:0 in the Pennsylvania-Maryland control pared with 6 type 2 and 9 non -type 2 strains in non-AIDS group, 78:10:12 in the California control group, and 80:10:4 PML patients. The tendency toward an increased number of in the PML group with 3 patients (6%) of unknown ethnicity. type 2 strains in AIDS PML was not statistically significant (P Å .66).
Statistical Significance of Differing JCV type Distributions
Besides the 41 PML strains reported in this study, the statistiDiscussion cal analysis included JCV strains from 11 PML patients described by Ault and Stoner [24] . These samples from 9 white
This study provides the first evidence that JCV type 2 can be identified more frequently in tissue from patients with PML and 2 African-American persons came from eastern and central states of the United States. This earlier study characterized than in urine samples from controls without PML. The other JCV genotypes found in the United States are types 1, 3, and JCV in brain tissue of 6 AIDS and 5 non-AIDS PML patients, of which 6 were positive for JCV type 1 and 5 were positive 4. The higher proportion of JCV type 2 strains in PML-affected tissue indicates that infection with this genotype is associated for JCV type 2. To determine whether the frequency of JCV infection with non -type 2 strains.
As outlined here and elsewhere [17, 27] , JCV strains from the urinary tract and central nervous system of a PML patient
